Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 477 Jan 1 – Oct 25, 2026
- Disclosed funding
- $20.2B 403 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
 Amani TherapeuticsCompany profile Biotechnology company developing combination medicines for serious neuropsychiatric disorders. Biotechnology company developing combination medicines for serious neuropsychiatric disorders. | $25M | Series A | Biotech | United States | Investors | |
| OC Oryon Cell TherapiesCompany profile Develops autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders Develops autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders | $21M | Series A | Biotech | United States | Investors | |
 Earendil LabsCompany profile Earendil Labs develops protein therapeutics using AI models coupled with experimental antibody discovery and validation. Earendil Labs develops protein therapeutics using AI models coupled with experimental antibody discovery and validation. | Undisclosed | Financing rounds disclosureUndisclosed | Biotech | United States | Investors | |
| CT Congruence TherapeuticsCompany profile Develops small molecule correctors for diseases of protein misfolding Develops small molecule correctors for diseases of protein misfolding | $39.5M | Series B | Biotech | Canada | Investors | |
| HU Health UniverseCompany profile Provides AI infrastructure for healthcare organizations to integrate and govern autonomous agents Provides AI infrastructure for healthcare organizations to integrate and govern autonomous agents | $6M | Seed | Biotech, Healthtech | United States | Investors | |
| EL Elea & LiliCompany profile Commercialises cellulose-based biodegradable absorbent materials for hygiene and agriculture Commercialises cellulose-based biodegradable absorbent materials for hygiene and agriculture | €2.5M | Seed | Biotech, Climate tech | Finland | Investors | |
| ET Excalipoint TherapeuticsCompany profile Develops next-generation T-cell engager therapies for cancer and autoimmune diseases Develops next-generation T-cell engager therapies for cancer and autoimmune diseases | $27.7M | Seed+Seed | Biotech | China | Investors | |
| CT Crossbow Therapeutics develops antibody therapies for cancer. | $77M | Series B | Biotech | United States | Investors | |
| CS Condor SoftwareCompany profile Provides financial intelligence platform for life sciences companies to unify clinical operational and financial data Provides financial intelligence platform for life sciences companies to unify clinical operational and financial data | $24M | Series A | Biotech | United States | Investors | |
| R RiviaCompany profile Builds a data engine for clinical trial intelligence to unify fragmented data and enable AI-driven insights Builds a data engine for clinical trial intelligence to unify fragmented data and enable AI-driven insights | $15M | Series A | Biotech, Healthtech | Switzerland | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
23rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.